Last year was a big year for biosimilars in the United States with the number of FDA-approved biosimilars nearly doubling and major policy and regulatory developments taking place in 2018.
Kelly Davio, senior editor of AJMC's The Center for Biosimilars, highlights recent progress, how the US market compares with Europe, and what remains to be seen.
Read more:
The Center for Biosimilars: https://www.centerforbiosimilars.com/
Stakeholders Weigh In on the Key Biosimilar Developments of 2018: https://www.centerforbiosimilars.com/news/stakeholders-weigh-in-on-the-key-biosimilar-developments-of-2018
Coherus Confirms That It Has Launched Its Pegfilgrastim Biosimilar, Udenyca: https://www.centerforbiosimilars.com/news/coherus-confirms-that-it-has-launched-its-pegfilgrastim-biosimilar-udenyca
FDA Releases Biosimilar Action Plan: https://www.centerforbiosimilars.com/news/fda-releases-biosimilar-action-plan
Pfizer Launches Epoetin Alfa Biosimilar, Retacrit, at 33.5% Discount to Reference Epogen: https://www.centerforbiosimilars.com/news/pfizer-launches-epoetin-alfa-biosimilar-retacrit-at-335-discount-to-reference-epogen
Pfizer Becomes Latest to Settle With AbbVie Over Humira: https://www.centerforbiosimilars.com/news/pfizer-becomes-latest-to-settle-with-abbvie-over-humira
